Absci and Invetx Partner to Bring Generative AI Drug Creation Platform to Animal Health

Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applicationsVANCOUVER, Wash. and BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, and Invetx, a pioneer in protein-based therapeutics for animal health, today announced a strategic partnership to harness Absci’s AI Drug Creation models to create an innovative Half-Life Extension ...